Annidis Corporation Appoints Dr. Rob Devenyi to Board of Directors

OTTAWA, Nov. 17, 2011 /CNW/ - Annidis Corporation (TSX-V:RHA), creator of the Annidis RHATM imaging technology that assists eye-care professionals screen, detect, diagnose and manage ocular diseases, today announced that Dr. Robert G. Devenyi, the Ophthalmologist-in-Chief and Director of Retinal Services at the Donald K. Johnson Eye Center at the University Health Network (UHN) has joined the Company's Board of Directors, and will replace Mr. Tim McCunn as a Director.

Dr. Devenyi is also a Professor of Ophthalmology and Vision Sciences at the University of Toronto, and the Team Ophthalmologist for the Toronto Maple Leafs. He has worked at the Hospital for Sick Children, and been on staff at the University Health Network since 1988.

"Robert comes from a very strong academic and industry background, and his addition to our Board demonstrates his confidence in our unique ocular pathology management system," said Mr. Mike Mueller, the Chairman of Annidis Corporation. "During the year we have made a number of strategic moves to develop a strong business platform, and with the degree of experience and expertise Robert brings to our Board, we believe we are well positioned to continue building momentum along our aggressive growth path across Canada and the U.S."

"As a practicing ophthalmologist, I believe the RHA ocular pathology management system has extensive clinical and research use, and could develop to be a standard tool in diagnosing ocular disease," said Dr. Devenyi. "My decision to join the Board of Annidis was primarily based on my experience working with the RHA system, and was impressed by its effectiveness in detecting and managing various ocular diseases."

Dr. Devenyi graduated summa cum laude from University of Toronto's School of Medicine and completed his Ophthalmology residency at the University of Toronto. He then did further training in the subspecialty of Vitreoretinal Surgery at the Medical College of Wisconsin, in Milwaukee, Wisconsin.

In keeping with Annadis' compensation structure, Dr. Devenyi will not receive any cash remuneration. Dr. Devenyi has been allocated stock options for his service, which is part of the allocation of options previously approved and reported in September 2011. This is in line with the Company's policy, as the Directors, Chairman and CEO are all compensated exclusively with options, which aligns their interest with that of shareholders.

"On behalf of the Board, I'd like to thank Tim for his leadership and contribution as a director for Annidis. The support he has provided to the Company through our early stage to bring us where we are has been invaluable." continued Mr. Mueller.

About Annidis Corporation

Annidis (TSX-V:RHA) is dedicated to researching and developing instrumentation to assist in the early detection and monitoring of diseases of the eye. The Company's RHATM is an ocular pathology management system that integrates advanced multi-spectral imaging and analytic software for early detection and management of ocular pathologies such as glaucoma, age-related macular degeneration and diabetic retinopathy. The RHA system is the result of a multiyear research and development effort by the Annidis team in collaboration with leading eye care professionals and researchers in Canada including the Ottawa Eye Institute, Toronto Western Hospital, the School of Optometry in Montreal and numerous optometric clinics in Ontario.

This news release may contain "forward-looking information" within the meaning of applicable Canadian securities legislation. Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope", and "continue" (or the negative thereof), and words and expressions of similar import are intended to identify forward-looking statements.  Certain material factors or assumptions are implied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company's Annual Information Form and other such filings with Canadian securities regulatory authorities, such as the applicability of patents and proprietary technology; possible patent ligation; regulatory approval of products in development; changes in government regulation or regulatory approval processes; government and third party reimbursement; dependence on strategic partnerships; intensifying competition; rapid technological change in the industry; anticipated future losses; the ability to access capital; and the ability to attract and retain key personnel.  All forward-looking information presented herein should be considered in conjunction with such filings. Except as required by Canadian securities laws, the Corporation does not undertake to update any forward-looking statements; such statements speak only as of the date made.

SOURCE Annidis Corporation

For further information:

Gerald Slemko, CEO
Annidis Corporation
(519) 672-1524
Email: geralds@annidis.com

Babak Pedram
TMX Equicom
(416) 815-0700 ext. 264
Email: bpedram@equicomgroup.com


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.